Inclusion Criteria:

1. Provision of signed written informed consent.

2. Diagnosis:

1. Part I: Histologically or cytologically confirmed diagnosis of cancer which is
not amenable to standard therapy, is refractory to standard therapy or for which
no standard therapy exists.

2. Part II: Histologically or cytologically confirmed diagnosis of advanced or
metastatic cancer of the pancreas, ovary, lung (NSCL), breast, bladder or NHL
not amenable to standard therapy, refractory to standard therapy or for which no
standard therapy exists who have been previously treated with gemcitabine.

3. Age ≥ 18 years.

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 5. Life
expectancy of ≥ 12 weeks.

6. Disease measurability:

1. Part I (Dose-escalation):

Patients must have a measurable (as per RECIST criteria version 1.1) and/or evaluable
disease (e.g., cytologically or radiologically detectable disease such as ascites,
peritoneal deposits, or lesions which do not fulfill RECIST criteria version 1.1 for
measurable disease).

2. Part II (expansion cohort):

Patients must have at least one measurable disease lesion as per the RECIST criteria
version 1.1.

7. Formalin Fixed Paraffin-Embedded (FFPE) archival tumour tissue available (for Part
II only). Fresh biopsies will be required if no FFPE tumour tissues available (for
Part II only).

8. Adequate bone marrow function as defined by: WBC of ≥ 3 x109/L, ANC of ≥ 1.5 x
109/L, platelet count of ≥ 100.0 x 109/L, and hemoglobin of ≥ 10 g/dL.

9. Adequate liver function, as determined by: Serum total bilirubin ≤1.5 x ULN (≤2.5
x ULN if liver metastases), AST and ALT ≤ 2.5 x ULN (≤ 5 x ULN if liver metastases).

10. Adequate renal function assessed by at least one of the following: 1) Serum
creatinine ≤ 1.5 x ULN; or 2) creatinine clearance estimate of ≥ 60 mL/min in male
and ≥ 50 mL/min in female (as calculated according to Cockcroft-Gault formula).

11. Ability to comply with protocol requirements. 12. Female patients must be
postmenopausal (12 months of amenorrhea), surgically sterile or they must agree to
use a physical method of contraception. Oral or injectable contraceptive agents
cannot be the sole method of contraception. Male patients must be surgically sterile
or agree to use a barrier method of contraception.

13. Female patients of child-bearing potential must have a negative serum pregnancy
test within the seven days prior to the first study drug administration.

Exclusion Criteria:

1. History of allergic reactions attributed to previous gemcitabine treatment.

2. Symptomatic CNS or leptomeningeal metastases

3. Prior chemotherapy, radiotherapy (other than short cycle of palliative
radiotherapy for bone pain), or immunotherapy within 28 days of first receipt of
study drug (within 6 weeks for nitrosoureas and mitomycin C). Hormone therapy
within 14 days of first receipt of study drug.

4. Prior toxicities from chemotherapy or radiotherapy which have not regressed to
Grade ≤ 1 severity (NCI-CTCAE version 4.0) apart from neuropathy and alopecia.

5. Another active cancer (excluding basal cell carcinoma or cervical
intraepithelial neoplasia (CIN/cervical in situ or melanoma in situ; Part II
only).

6. Patients with uncontrolled concomitant illness, active infection requiring i.v.
antibiotics, or uncontrolled infections, or a fever >38.5°C on the day of
scheduled dosing.

7. Patients will serious illnesses, medical conditions, or other medical history,
including laboratory results, which, in the investigator's opinion, would be
likely to interfere with a patient's participation in the study, or with the
interpretation of the results.

8. Known HIV or known active Hepatitis B or C.

9. Any condition (e.g., known or suspected poor compliance, psychological
instability, geographical location, etc.) that, in the judgment of the
investigator, may affect the patient's ability to sign the informed consent and
undergo study procedures.

-